Correlating structure and function of drug-metabolizing enzymes: Progress and ongoing challenges

Drug Metabolism and Disposition

Volumn 42, Issue 1, 2014, Pages 9-22

  Johnson, Eric F ^a   Connick, J Patrick ^b   Reed, James R ^b   Backes, Wayne L ^b   Desai, Manoj C ^c   Xu, Lianhong ^c   Estrada, D Fernando ^d   Laurence, Jennifer S ^d   Scott, Emily E ^d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GILEAD SCIENCES   (United States)

^d UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AJMALICINE; AMLODIPINE; AROMATASE INHIBITOR; ATAZANAVIR; COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; CYTOCHROME B5; CYTOCHROME P450; CYTOCHROME P450 17A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B4; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ELVITEGRAVIR; FLURBIPROFEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; PRINOMASTAT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; RITONAVIR; THIORIDAZINE; UNCLASSIFIED DRUG;

BINDING AFFINITY; BREAST CANCER; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; DISORDERS OF LIPID METABOLISM; DRUG CLEARANCE; DRUG DESIGN; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; ENDOPLASMIC RETICULUM; ENZYME ACTIVE SITE; ENZYME SUBSTRATE COMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIGAND BINDING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; XENOBIOTIC METABOLISM;

CELL MEMBRANE; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; HUMANS; METABOLIC DETOXICATION, DRUG; NADPH-FERRIHEMOPROTEIN REDUCTASE; PROTEIN INTERACTION DOMAINS AND MOTIFS;

EID: 84890721702     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.054627     Document Type: Conference Paper

References (96)

1. Ahuja S, Jahr N, Im SC, Vivekanandan S, Popovych N, Le Clair SV, Huang R, Soong R, Xu J, and Yamamoto K, et al. (2013) A model of the membrane-bound cytochrome b5-cytochrome P450 complex from NMR and mutagenesis data. J Biol Chem 288:22080-22095.
2. Akhtar MK, Kelly SL, and Kaderbhai MA (2005) Cytochrome b(5) modulation of 17alpha hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis. J Endocrinol 187:267-274. (Pubitemid 41685186)
3. Asciutto EK, Young MJ, Madura J, Pochapsky SS, and Pochapsky TC (2012) Solution structural ensembles of substrate-free cytochrome P450(cam). Biochemistry 51:3383-3393.
4. Backes WL, Batie CJ, and Cawley GF (1998) Interactions among P450 enzymes when combined in reconstituted systems: formation of a 2B4-1A2 complex with a high affinity for NADPH-cytochrome P450 reductase. Biochemistry 37:12852-12859. (Pubitemid 28433517)
5. Bass MB, Paulsen MD, and Ornstein RL (1992) Substrate mobility in a deeply buried active site: analysis of norcamphor bound to cytochrome P-450cam as determined by a 201-psec molecular dynamics simulation. Proteins 13:26-37.
6. Berka K, Hendrychová T, Anzenbacher P, and Otyepka M (2011) Membrane position of ibu-profen agrees with suggested access path entrance to cytochrome P450 2C9 active site. J Phys Chem A 115:11248-11255.
7. Bridges A, Gruenke L, Chang YT, Vakser IA, Loew G, and Waskell L (1998) Identification of the binding site on cytochrome P450 2B4 for cytochrome b5 and cytochrome P450 reductase. J Biol Chem 273:17036-17049. (Pubitemid 28311737)
8. Chumsri S, Sabnis GJ, Howes T, and Brodie AM (2011) Aromatase inhibitors and xenograft studies. Steroids 76:730-735.
9. Cojocaru V, Balali-Mood K, Sansom MS, and Wade RC (2011) Structure and dynamics of the membrane-bound cytochrome P450 2C9. PLOS Comput Biol 7:e1002152.
10. Cojocaru V, Winn PJ, and Wade RC (2007) The ins and outs of cytochrome P450s. Biochim Biophys Acta 1770:390-401. (Pubitemid 46136742)
11. Collins JR and Loew GH (1988) Theoretical study of the product specificity in the hydroxylation of camphor, norcamphor, 5, 5-difluorocamphor, and pericyclocamphanone by cytochrome P-450cam. J Biol Chem 263:3164-3170. (Pubitemid 18072766)
12. Cruciani G, Carosati E, De Boeck B, Ethirajulu K, Mackie C, Howe T, and Vianello R (2005) MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem 48:6970-6979. (Pubitemid 41533118)
13. Davydov DR (2011) Microsomal monooxygenase as a multienzyme system: the role of P450-P450 interactions. Expert Opin Drug Metab Toxicol 7:543-558.
14. Davydov DR, Knyushko TV, and Hoa GH (1992) High pressure induced inactivation of ferrous cytochrome P-450 LM2 (IIB4) CO complex: evidence for the presence of two conformers in the oligomer. Biochem Biophys Res Commun 188:216-221.
15. Davydov DR, Sineva EV, Sistla S, Davydova NY, Frank DJ, Sligar SG, and Halpert JR (2010) Electron transfer in the complex of membrane-bound human cytochrome P450 3A4 with the flavin domain of P450BM-3: the effect of oligomerization of the heme protein and intermittent modulation of the spin equilibrium. Biochim Biophys Acta 1797:378-390.
16. de Groot MJ (2006) Designing better drugs: predicting cytochrome P450 metabolism. Drug Discov Today 11:601-606.
17. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, and White K, et al.; GS-236-0103 Study Team (2012) Co-formulated elvite-gravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 379:2429-2438.
18. DeVore NM and Scott EE (2012) Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature 482:116-119.
19. Ekroos M and Sjögren T (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci USA 103:13682-13687. (Pubitemid 44413967)
20. Estabrook RW, Hildebrandt AG, Baron J, Netter KJ, and Leibman K (1971) A new spectral intermediate associated with cytochrome P-450 function in liver microsomes. Biochem Biophys Res Commun 42:132-139.
21. Estrada DF, Laurence JS, and Scott EE (2013) Substrate-modulated cytochrome P450 17A1 and cytochrome b5 interactions revealed by NMR. J Biol Chem 288:17008-17018.
22. Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd P, DeJesus E, Antunes F, Arastéh K, Moyle G, Rizzardini G, and Fehr J (2013) Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/ tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis 208(1):32-9.
23. Gallant JE (2004) Protease-inhibitor boosting in the treatment- experienced patient. AIDS Rev 6: 226-233. (Pubitemid 40227884)
24. Gao Q, Doneanu CE, Shaffer SA, Adman ET, Goodlett DR, and Nelson SD (2006) Identification of the interactions between cytochrome P450 2E1 and cytochrome b5 by mass spectrometry and site-directed mutagenesis. J Biol Chem 281:20404-20417. (Pubitemid 44065814)
25. Geller DH, Auchus RJ, and Miller WL (1999) P450c17 mutations R347H and R358Q selectively disrupt 17, 20-lyase activity by disrupting interactions with P450 oxidoreductase and cyto-chrome b5. Mol Endocrinol 13:167-175. (Pubitemid 29022289)
26. Groves JT, McClusky GA, White RE, and Coon MJ (1978) Aliphatic hydroxylation by highly purified liver microsomal cytochrome P-450. Evidence for a carbon radical intermediate. Biochem Biophys Res Commun 81:154-160.
27. Halpert JR (2011) Structure and function of cytochromes P450 2B: from mechanism-based inactivators to X-ray crystal structures and back. Drug Metab Dispos 39:1113-1121.
28. Hasemann CA, Kurumbail RG, Boddupalli SS, Peterson JA, and Deisenhofer J (1995) Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 3:41-62.
29. Hazai E and Kupfer D (2005) Interactions between CYP2C9 and CYP2C19 in reconstituted binary systems influence their catalytic activity: possible rationale for the inability of CYP2C19 to catalyze methoxychlor demethylation in human liver microsomes. Drug Metab Dispos 33: 157-164. (Pubitemid 40023527)
30. Hiruma Y, Hass MA, Kikui Y, Liu WM, Olmez B, Skinner SP, Blok A, Kloosterman A, Koteishi H, and Löhr F, et al. (2013) The structure of the cytochrome P450cam-putidaredoxin complex determined by paramagnetic NMR spectroscopy and crystallography. J Mol Biol DOI:10.1124/pr.55.3.4 [published ahead of print].
31. Hu G, Johnson EF, and Kemper B (2010) CYP2C8 exists as a dimer in natural membranes. Drug Metab Dispos 38:1976-1983.
32. Ibeanu GC, Ghanayem BI, Linko P, Li L, Pederson LG, and Goldstein JA (1996) Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity. J Biol Chem 271:12496-12501. (Pubitemid 26160921)
33. Im SC and Waskell L (2011) The interaction of microsomal cytochrome P450 2B4 with its redox partners, cytochrome P450 reductase and cytochrome b(5). Arch Biochem Biophys 507:144-153.
34. Jamakhandi AP, Kuzmic P, Sanders DE, and Miller GP (2007) Global analysis of protein-protein interactions reveals multiple CYP2E1-reductase complexes. Biochemistry 46:10192-10201. (Pubitemid 47381277)
35. Johnson EF and Stout CD (2013) Structural diversity of eukaryotic membrane cytochrome p450s. J Biol Chem 288:17082-17090.
36. Jones JP, Mysinger M, and Korzekwa KR (2002) Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction. Drug Metab Dispos 30:7-12. (Pubitemid 34016934)
37. Jung F, Griffin KJ, Song W, Richardson TH, Yang M, and Johnson EF (1998) Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19. Biochemistry 37:16270-16279. (Pubitemid 28536263)
38. Kelly SL, Lamb DC, Cannieux M, Greetham D, Jackson CJ, Marczylo T, Ugochukwu C, and Kelly DE (2001) An old activity in the cytochrome P450 superfamily (CYP51) and a new story of drugs and resistance. Biochem Soc Trans 29:122-128. (Pubitemid 32587490)
39. Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA, Green BE, Fino L, Park CH, and Kong XP, et al. (1995) ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 92:2484-2488.
40. Klose TS, Ibeanu GC, Ghanayem BI, Pedersen LG, Li L, Hall SD, and Goldstein JA (1998) Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. Arch Biochem Biophys 357:240-248. (Pubitemid 28419205)
41. Korzekwa KR, Jones JP, and Gillette JR (1990) Theoretical studies on cytochrome P-450 mediated hydroxylation: A predictive model for hydrogen atom abstractions. J Am Chem Soc 112: 7042-7046. (Pubitemid 20319136)
42. Lee-Robichaud P, Akhtar ME, Wright JN, Sheikh QI, and Akhtar M (2004) The cationic charges on Arg347, Arg358 and Arg449 of human cytochrome P450c17 (CYP17) are essential for the enzyme's cytochrome b5-dependent acyl-carbon cleavage activities. J Steroid Biochem Mol Biol 92:119-130. (Pubitemid 39535853)
43. Li H and Poulos TL (1997) The structure of the cytochrome p450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid. Nat Struct Biol 4:140-146. (Pubitemid 27066389)
44. Naffin-Olivos JL and Auchus RJ (2006) Human cytochrome b5 requires residues E48 and E49 to stimulate the 17, 20-lyase activity of cytochrome P450c17. Biochemistry 45:755-762. (Pubitemid 43122240)
45. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, and Estabrook RW, et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42. (Pubitemid 26096749)
46. Nunez M, Guittet E, Pompon D, van Heijenoort C, and Truan G (2010) NMR structure note: oxidized microsomal human cytochrome b5. J Biomol NMR 47:289-295.
47. O'Brien SE and de Groot MJ (2005) Greater than the sum of its parts: combining models for useful ADMET prediction. J Med Chem 48:1287-1291. (Pubitemid 40270476)
48. Ozalp C, Szczesna-Skorupa E, and Kemper B (2005) Bimolecular fluorescence complementation analysis of cytochrome p450 2c2, 2e1, and NADPH-cytochrome p450 reductase molecular interactions in living cells. Drug Metab Dispos 33:1382-1390. (Pubitemid 41196983)
49. Peng HM and Auchus RJ (2013) The action of cytochrome b(5) on CYP2E1 and CYP2C19 activities requires anionic residues D58 and D65. Biochemistry 52:210-220.
50. Peterson JA, Ebel RE, O'Keeffe DH, Matsubara T, and Estabrook RW (1976) Temperature dependence of cytochrome P-450 reduction. A model for NADPH-cytochrome P-450 re-ductase:cytochrome P-450 interaction. J Biol Chem 251:4010-4016.
51. Poulos TL, Finzel BC, and Howard AJ (1987) High-resolution crystal structure of cytochrome P450cam. J Mol Biol 195:687-700.
52. Ravichandran KG, Boddupalli SS, Hasermann CA, Peterson JA, and Deisenhofer J (1993) Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. Science 261:731-736. (Pubitemid 23278388)
53. Reed JR and Backes WL (2012) Formation of P450 · P450 complexes and their effect on P450 function. Pharmacol Ther 133:299-310.
54. Reed JR, Connick JP, Cheng D, Cawley GF, and Backes WL (2012) Effect of homomeric P450-P450 complexes on P450 function. Biochem J 446:489-497.
55. Reed JR, Eyer M, and Backes WL (2010) Functional interactions between cytochromes P450 1A2 and 2B4 require both enzymes to reside in the same phospholipid vesicle: evidence for physical complex formation. J Biol Chem 285:8942-8952.
56. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448. (Pubitemid 34311090)
57. Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580. (Pubitemid 27293618)
58. Reynald RL, Sansen S, Stout CD, and Johnson EF (2012) Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19. J Biol Chem 287:44581-44591.
59. Rittle J and Green MT (2010) Cytochrome P450 compound I: capture, characterization, and C-H bond activation kinetics. Science 330:933-937.
60. Rui L, Pochapsky SS, and Pochapsky TC (2006) Comparison of the complexes formed by cytochrome P450cam with cytochrome b5 and putidaredoxin, two effectors of camphor hy-droxylase activity. Biochemistry 45:3887-3897.
61. Sansen S, Yano JK, Reynald RL, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2007) Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 282:14348-14355. (Pubitemid 47100434)
62. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, and Yale K, et al.; GS-US-236-0102 study team (2012) Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 379:2439-2448.
63. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, and Johnson EF (2008) Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglita-zone, felodipine, and 9-cis-retinoic acid. J Biol Chem 283:17227-17237.
64. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, and Johnson EF (2004) Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 279:9497-9503. (Pubitemid 38296017)
65. Sevrioukova IF and Poulos TL (2012) Interaction of human cytochrome P4503A4 with ritonavir analogs. Arch Biochem Biophys 520:108-116.
66. Shen AL, Porter TD, Wilson TE, and Kasper CB (1989) Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. J Biol Chem 264:7584-7589. (Pubitemid 19119176)
67. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, and Sato M, et al. (2008) Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 82:764-774.
68. Singer SJ (1975) Architecture and Topography of Biologic Membranes, HP Publishing Co., Inc., New York, New York.
69. Sirim D, Widmann M, Wagner F, and Pleiss J (2010) Prediction and analysis of the modular structure of cytochrome P450 monooxygenases. BMC Struct Biol 10:34-46.
70. Skinner AL and Laurence JS (2008) High-field solution NMR spectroscopy as a tool for assessing protein interactions with small molecule ligands. J Pharm Sci 97:4670-4695.
71. Sligar SG (1976) Coupling of spin, substrate, and redox equilibria in cytochrome P450. Biochemistry 15:5399-5406.
72. Subramanian M, Low M, Locuson CW, and Tracy TS (2009) CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis. Drug Metab Dispos 37:1682-1689.
73. Subramanian M, Tam H, Zheng H, and Tracy TS (2010) CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus. Drug Metab Dispos 38:1003-1009.
74. Sulc M, Jecmen T, Snajdrova R, Novak P, Martinek V, Hodek P, Stiborova M, and Hudecek J (2012) Mapping of interaction between cytochrome P450 2B4 and cytochrome b5: the first evidence of two mutual orientations. Neuroendocrinol Lett 33 (Suppl 3):41-47.
75. Sun H and Scott DO (2010) Structure-based drug metabolism predictions for drug design. Chem Biol Drug Des 75:3-17.
76. Szczesna-Skorupa E, Chen CD, and Kemper B (2000) Cytochromes P450 2C1/2 and P450 2E1 are retained in the endoplasmic reticulum membrane by different mechanisms. Arch Biochem Biophys 374:128-136. (Pubitemid 30120245)
77. Tripathi S, Li H, and Poulos TL (2013) Structural basis for effector control and redox partner recognition in cytochrome P450. Science 340:1227-1230.
78. Tsao CC, Wester MR, Ghanayem B, Coulter SJ, Chanas B, Johnson EF, and Goldstein JA (2001) Identification of human CYP2C19 residues that confer S-mephenytoin 49-hydroxylation activity to CYP2C9. Biochemistry 40:1937-1944. (Pubitemid 32165662)
79. Walsh AA, Szklarz GD, and Scott EE (2013) Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism. J Biol Chem 288:12932-12943.
80. Wang A, Savas U, Hsu MH, Stout CD, and Johnson EF (2012) Crystal structure of human cytochrome P450 2D6 with prinomastat bound. J Biol Chem 287:10834-10843.
81. Wang A, Savas U, Stout CD, and Johnson EF (2011) Structural characterization of the complex between alpha-naphthoflavone and human cytochrome P450 1B1. J Biol Chem 286: 5736-5743.
82. Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, and Zhou SF (2009) New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev 41:573-643.
83. Wang M, Roberts DL, Paschke R, Shea TM, Masters BS, and Kim JJ (1997) Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN-and FAD-containing enzymes. Proc Natl Acad Sci USA 94:8411-8416. (Pubitemid 27335052)
84. Wester MR, Johnson EF, Marques-Soares C, Dijols S, Dansette PM, Mansuy D, and Stout CD (2003) Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution: evidence for an induced fit model of substrate binding. Biochemistry 42: 9335-9345. (Pubitemid 36959241)
85. Williams PA, Cosme J, Sridhar V, Johnson EF, and McRee DE (2000) Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 5:121-131. (Pubitemid 30105441)
86. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683-686. (Pubitemid 39006760)
87. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, and Watkins PB (2000) The human CYP3A subfamily: practical considerations. Drug Metab Rev 32:339-361. (Pubitemid 32001911)
88. Xia C, Panda SP, Marohnic CC, Martásek P, Masters BS, and Kim JJ (2011) Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency. Proc Natl Acad Sci USA 108: 13486-13491.
89. Xu L and Desai MC (2009) Pharmacokinetic enhancers for HIV drugs. Curr Opin Investig Drugs 10:775-786.
90. Xu L, Liu HC, Murray BP, Callebaut C, Lee MS, Hong A, Strickley RG, Tsai LK, Stray KM, Wang Y, Rhodes GR, and Desai M.C., et al. (2010) Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett 1: 209-213.
91. Yamazaki H, Gillam EM, Dong MS, Johnson WW, Guengerich FP, and Shimada T (1997) Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. Arch Biochem Biophys 342:329-337. (Pubitemid 27251255)
92. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091-38094. (Pubitemid 39295952)
93. Yin H, Anders MW, Korzekwa KR, Higgins L, Thummel KE, Kharasch ED, and Jones JP (1995) Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. Proc Natl Acad Sci USA 92:11076-11080.
94. Zanger UM and Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103-141.
95. Zanger UM, Turpeinen M, Klein K, and Schwab M (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093-1108.
96. Zhao C, Gao Q, Roberts AG, Shaffer SA, Doneanu CE, Xue S, Goodlett DR, Nelson SD, and Atkins WM (2012) Cross-linking mass spectrometry and mutagenesis confirm the functional importance of surface interactions between CYP3A4 and holo/apo cytochrome b(5). Biochemistry 51:9488-9500.